论文部分内容阅读
目的观察索拉非尼联合多柔比星对人乳腺癌MDA-MB-231细胞和人肺癌A549细胞的抑制作用。方法不同浓度索拉非尼联合多柔比星处理人乳腺癌MDA-MB-231细胞和人肺癌A549细胞。①以CCK-8法检测处理24、48和72 h后MDA-MB-231和A549的抑制率;②以细胞划痕试验观察受试细胞的迁移能力;③以印迹试验检测处理24 h后MDAMB-231细胞内P-ERK和Bcl-2的表达情况。结果索拉非尼联合多柔比星能显著抑制人肺癌A549细胞和人乳腺癌MDAMB-231细胞的体外增殖,且具时间依赖性;人乳腺癌MDA-MB-231细胞经不同浓度索拉非尼联合多柔比星处理24 h,P-ERK和Bcl-2蛋白的表达明显下调并呈剂量依赖性。结论索拉非尼联合多柔比星具有抑制人乳腺癌MDA-MB-231细胞和人肺癌A549细胞的增殖,诱导细胞凋亡的作用。
Objective To observe the inhibitory effect of sorafenib combined with doxorubicin on human breast cancer MDA-MB-231 cells and human lung cancer A549 cells. Methods Sorafenib and doxorubicin were used to treat human breast cancer MDA-MB-231 cells and human lung cancer A549 cells. ① The inhibitory rates of MDA-MB-231 and A549 were detected by CCK-8 assay 24, 48 and 72 h after treatment; ② The migration ability of test cells was observed by cell scratch test; ③ The expression of MDAMB -231 cells in the expression of P-ERK and Bcl-2. Results Sorafenib combined with doxorubicin could significantly inhibit the proliferation of human lung cancer A549 cells and human breast cancer MDAMB-231 cells in vitro and in a time-dependent manner. Human breast cancer MDA-MB-231 cells were treated with sorafenib at different concentrations In combination with Doxorubicin, the expression of P-ERK and Bcl-2 protein was significantly down-regulated in a dose-dependent manner. Conclusion Sorafenib combined with doxorubicin inhibits the proliferation and induces apoptosis of human breast cancer MDA-MB-231 cells and human lung cancer A549 cells.